These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 20716657)
1. Cost of illness from the public payers' perspective in patients with ankylosing spondylitis in rheumatological care. Strömbeck B; Englund M; Bremander A; Jacobsson LT; Kedza L; Kobelt G; Petersson IF J Rheumatol; 2010 Nov; 37(11):2348-55. PubMed ID: 20716657 [TBL] [Abstract][Full Text] [Related]
2. Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Boonen A; Brinkhuizen T; Landewé R; van der Heijde D; Severens JL Ann Rheum Dis; 2010 Jun; 69(6):1123-8. PubMed ID: 20439293 [TBL] [Abstract][Full Text] [Related]
3. A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Boonen A Nat Clin Pract Rheumatol; 2006 Oct; 2(10):546-53. PubMed ID: 17016480 [TBL] [Abstract][Full Text] [Related]
4. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Boonen A; van den Heuvel R; van Tubergen A; Goossens M; Severens JL; van der Heijde D; van der Linden S Ann Rheum Dis; 2005 Mar; 64(3):396-402. PubMed ID: 15271773 [TBL] [Abstract][Full Text] [Related]
5. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514 [TBL] [Abstract][Full Text] [Related]
6. Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Krüger K; von Hinüber U; Meier F; Tian H; Böhm K; Jugl SM; Borchert K; Meise D; König C; Braun S Rheumatol Int; 2018 Nov; 38(11):2121-2131. PubMed ID: 30094685 [TBL] [Abstract][Full Text] [Related]
7. Healthcare costs and productivity losses directly attributable to ankylosing spondylitis. Rafia R; Ara R; Packham J; Haywood KL; Healey E Clin Exp Rheumatol; 2012; 30(2):246-53. PubMed ID: 22409861 [TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Van Tubergen A; Boonen A; Landewé R; Rutten-Van Mölken M; Van Der Heijde D; Hidding A; Van Der Linden S Arthritis Rheum; 2002 Oct; 47(5):459-67. PubMed ID: 12382292 [TBL] [Abstract][Full Text] [Related]
9. Costs and work limitation of patients with ankylosing spondylitis in China. Tu L; Rai JC; Cao S; Lin Z; Hu Z; Gu J Clin Exp Rheumatol; 2014; 32(5):661-6. PubMed ID: 25234798 [TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. Kobelt G; Andlin-Sobocki P; Maksymowych WP J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476 [TBL] [Abstract][Full Text] [Related]
11. Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Zhu TY; Tam LS; Lee VW; Hwang WW; Li TK; Lee KK; Li EK Rheumatology (Oxford); 2008 Sep; 47(9):1422-5. PubMed ID: 18635597 [TBL] [Abstract][Full Text] [Related]
12. Costs and quality of life of patients with ankylosing spondylitis in Canada. Kobelt G; Andlin-Sobocki P; Maksymowych WP J Rheumatol; 2006 Feb; 33(2):289-95. PubMed ID: 16465660 [TBL] [Abstract][Full Text] [Related]
14. The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey. Malhan S; Pay S; Ataman S; Dalkilic E; Dinc A; Erken E; Ertenli I; Ertugrul E; Gogus F; Hamuryudan V; Inanc M; Karaarslan Y; Karadag O; Karakoc Y; Keskin G; Kisacik B; Kiraz S; Oksel F; Oksuz E; Pirildar T; Sari I; Soy M; Senturk T; Taylan A Clin Exp Rheumatol; 2012; 30(2):202-7. PubMed ID: 22546069 [TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Kobelt G; Lindgren P; Singh A; Klareskog L Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of TNF-α inhibition in active ankylosing spondylitis: a systematic appraisal of the literature. Kirchhoff TD; Mittendorf T; Schmidt RE; Jablonka A; Merkesdal S Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):307-17. PubMed ID: 22812555 [TBL] [Abstract][Full Text] [Related]
17. Costs and quality of life of multiple sclerosis in Austria. Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339 [TBL] [Abstract][Full Text] [Related]
18. Functional disability predicts total costs in patients with ankylosing spondylitis. Ward MM Arthritis Rheum; 2002 Jan; 46(1):223-31. PubMed ID: 11817595 [TBL] [Abstract][Full Text] [Related]
19. Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005--a register-based approach. Bolin K; Gip C; Mörk AC; Lindgren B Diabet Med; 2009 Sep; 26(9):928-34. PubMed ID: 19719715 [TBL] [Abstract][Full Text] [Related]
20. [Cost-benefit analysis of [224Ra] radium chloride therapy for ankylosing spondylitis (Bekhterev's disease)]. Zhang Z; Siegert J; Maywald U; Kirch W Med Klin (Munich); 2007 Jul; 102(7):540-9. PubMed ID: 17634872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]